comprehensive -WSS

comprehensive

author：focus 2025-09-30 06:21:54 - browse：22241

President Joe Biden talks in the Roosevelt Room of the White House, in front of a painting of Theodore Roosevelt on a horse back — politics coverage from STAT — President Biden MANDEL NGAN/AFP via Getty Images

WASHINGTON — The White House is throwing its support behind a controversial authority that allows the government to undermine patent rights for certain high-priced medicines. It’s an early step that could have major ramifications for the American pharmaceutical industry, depending on whether and how federal officials actually use the authority.

The administration issued a framework for the National Institutes of Health to more broadly use so-called “march-in rights” — a policy that allows it to invalidate patent rights from drugmakers whose products rely on federally funded research. The framework lays out when the agency might assert this authority, and endorse using a drug’s price in that determination.

“We’ll make clear that when drug companies won’t sell taxpayer funded drugs at reasonable prices, we will be prepared to allow other companies to provide those drugs for less,” White House National Economic Advisor Lael Brainard told reporters. “These authorities are in existing laws, the last administration just didn’t want to allow them to be used in this way.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： CDC wastewater surveillance dashboard to track bird flu hotspots

entertainment

WSS

How to improve immunocompromised access to mAb treatments

There's an unseen cost to disruptive road

FDA endorses new sterilization method for medical devices

Study: AI not yet building 'n

Software glitch causes Tandem insulin pump to shutdown, FDA warns

Brain worms: The science behind RFK Jr.'s parasitic infection

Wikipedia

comprehensive

hotspot

In Memoriam: Notable people who died in 2023

Dana Farber says 6 studies to be retracted and 31 corrected

BioMarin wins approval for gene therapy to treat hemophilia A

H5N1 bird flu: what we're starting to learn about infection in cows

Apple is now the first public company to be valued at $3 trillion

Brain worms: The science behind RFK Jr.'s parasitic infection

Jerome Adams on the need for new antivirals for Covid

Immunocompromised patients offer clues on chronic Covid

Hollywood unions extend contract negotiations for actors

How to improve immunocompromised access to mAb treatments

hotspot

Shionogi licenses Pompe disease therapy from Maze Therapeutics

Prior authorization reform is both possible and imperative

Dog Aging Project founders on what lies ahead after losing funding

Alcohol isn't healthy after all. Will new dietary guidelines reflect that?

Pumping milk in bathrooms at health conferences is common

Update the Apgar Score to remove skin color

Wikipedia

entertainment

entertainment

Wikipedia